Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Zentalis Pharmaceuticals announced the FDA's partial clinical hold on azenosertib studies due to recent patient deaths.
What’s Happening With Tobacco Major Philip Morris Shares On Tuesday?
Following a subpoena from D.C. authorities, Philip Morris has suspended online sales of its Zyn nicotine pouches amid an investigation into compliance with local flavored product bans.
Zevra Therapeutics Selects Orsini As The Specialty Pharmacy Provider For OLPRUVA
Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA®
CEL-SCI Presents Head & Neck Cancer Data At IDDST Annual Congress In Budapest: Risk Of Death Cut In Half For Patients Treated With Multikine In The Target Population
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors73% survival for Multikine vs 45% in the control arm at 5
Tesla’s Chinese Rival NIO Unveils Plans For Nio IN 2024: Anticipates Launch of Second-Generation Nio Phone Amid Innovations
NIO gears up for Nio IN 2024, promising innovation with the launch of the second-generation Nio Phone amid strategic partnerships and advancements in EV technology
Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDPADVANCE Clinical Program Reflects Takeda's
FDA Approves Merck’s Pneumococcal Vaccine As First Shot Designed For Adults
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced endometrial carcinoma.
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With NRAS-Mutant Melanoma
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to dateFavorable mOS and mPFS demonstrated in pooled
Taysha Gene Therapies Announced Longer-term Clinical Data From Ongoing REVEAL Phase 1/2 Adolescent And Adult Trial And Initial Clinical Data From REVEAL Phase 1/2 Pediatric Trial Of TSHA-102 In Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen
Nvidia, Uber, Volvo Invests $200M In This Autonomous Trucking Startup
With this round of investment, Waabi is planning to launch its driverless trucks in Texas and expand operations to new geographies.